Asymmetric is running an account-based marketing (ABM) campaign for [1] using Salesforce as the campaign platform. As of the March 2026 prep call, the campaign is mid-sequence and showing healthy engagement signals, though client-side sales follow-through remains the primary gap.
| Metric | Value |
|---|---|
| Total accounts in ABM list | 249 |
| Total emails sent | 383 |
| Opens | 46 |
| Open rate | ~12% |
| Scheduling link clicks | 3 |
| Current sequence stage | Primarily step 3–4 |
The 12% open rate on cold outbound is considered solid. The presence of scheduling clicks indicates genuine purchase intent from a subset of contacts.
Two dashboards are maintained in Salesforce for this campaign:
The engagement summary's open-count report is the primary tool for identifying warm contacts. Contacts with 3 or more opens are flagged as high-engagement and represent the clearest sales follow-up opportunity.
Contacts who have opened campaign emails 3+ times should be prioritized for direct outreach by Bluepoint's sales team. The recommended approach:
Note: Automated LinkedIn outreach tools (e.g., Phantom Buster) are not recommended — they feel impersonal and risk LinkedIn account restrictions. Manual outreach is preferred.
Mark proposed two growth directions for the campaign:
Both options can be pursued simultaneously. The decision should be made with Bluepoint based on their capacity to handle increased inbound interest.
Cold ABM outreach typically requires 7–12 touchpoints before a prospect engages meaningfully. The current campaign is still early in that arc. Engagement metrics at this stage (opens, clicks) are leading indicators — not yet pipeline. Persistence and consistent follow-up are required to convert engagement into booked meetings.
Despite healthy campaign engagement, Bluepoint's internal sales activity is minimal:
The ABM campaign is generating awareness and engagement, but the bottleneck is Bluepoint's follow-through. The campaign cannot close deals on its own — it requires the sales team to act on warm signals.